{ }
In 2024, global IPO activity declined, with a 10% drop in the number of offerings to 1,215 and a 4% decrease in transaction value to $121 billion. The US market saw significant growth, while China's IPOs plummeted by over half, reflecting stark regional disparities influenced by deglobalization and interest rate changes. Switzerland's Galderma IPO ranked fifth globally, and experts express optimism for a market revival in 2025, driven by favorable conditions and potential deregulation in the US.
AstraZeneca is enhancing its global operations with a $3.5 billion investment in the U.S. through 2026, creating over 1,000 high-skilled jobs, while navigating challenges in China following leadership changes. Strong demand for cancer and rare-disease treatments has led to improved financial performance, prompting a raised sales outlook. The company’s strategic refresh includes new board appointments to bolster governance and digital capabilities, reflecting confidence in its growth trajectory.
IG
Dtravel, a decentralized vacation rental platform, has secured strategic investments from Modular Capital and Escape Velocity Crypto (EV3) to enhance its global peer-to-peer ecosystem. With 9,000 hosts across 110 countries and significant year-over-year growth, Dtravel aims to empower operators by eliminating middlemen through blockchain technology. CEO Cynthia Huang expressed optimism that these partnerships will accelerate the development of a transparent and community-driven travel marketplace.
The EuroStoxx 50 is expected to end 2024 with modest gains, reflecting a year of stagnation influenced by weak Chinese demand impacting luxury goods, rising risk premiums on French bonds, and concerns over US-Europe trade tensions. A technical analysis suggests a potential bullish breakout in early 2025, contingent on improved global economic conditions. However, a downturn remains possible if the economic outlook worsens.
IG
The global gene therapy market, valued at $7.54 billion in 2022, is projected to reach $41.38 billion by 2031, driven by increased R&D, favorable regulations, and collaborations between pharmaceutical companies and academic institutions. North America leads the market, with significant advancements in biotechnology and numerous clinical trials. Recent developments include Novartis's acquisition of a gene therapy candidate from Avrobio and Bristol-Myers Squibb's expansion of its cell therapy manufacturing network.
UBS is navigating challenges in China, led by Janice Hu, the new Country Head, as the bank grapples with a sluggish economy and seeks support from the Chinese state. The leadership includes a descendant of a former Communist Party General Secretary, highlighting the complexities of operating under Xi Jinping's policies.
UBS faces challenges in China due to Xi Jinping's policies promoting "universal prosperity," which discourage high executive salaries and wealth concentration. The sluggish economy, exacerbated by a real estate crisis, has led wealthy clients to shift assets abroad, complicating UBS's operations. The bank hopes for a gradual economic stimulus from the Chinese government to stabilize the market and boost private consumption.
Asian stocks mostly rose ahead of the Federal Reserve's final rate decision of the year, with Japan's Nikkei 225 slipping 0.2% despite a 3.8% increase in exports. Trading in Nissan shares was suspended after a 22% surge amid merger talks with Honda, while the Hang Seng and Shanghai Composite gained 0.6% and 0.7%, respectively. The S&P 500 is on track for a nearly 27% annual gain, as strong retail sales data raises questions about the need for further rate cuts.
World stocks are mixed as markets await the Federal Reserve's rate decision. European indices opened higher, while Japan's Nikkei 225 fell 0.7%. Nissan shares surged 23.7% amid collaboration talks with Honda, while U.S. retail sales exceeded expectations, hinting at a resilient economy.
Asian stocks mostly rose ahead of the Federal Reserve's rate decision, with Japan's Nikkei 225 slipping 0.2% despite a 3.8% increase in exports. Nissan's shares surged 22% amid merger talks with Honda, while the Hang Seng and Shanghai Composite gained 0.6% and 0.7%, respectively. The Fed is expected to announce a rate cut, but strong economic data may lead to a pause in January.
Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

MachinaCore is a highly modular and scalable system that allows users to build custom widgets and tools tailored to their specific financial data needs, while seamlessly integrating with other MachinaLabs products, like Machinary, MachinaAI Modules and MachinaTrader.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.